According to reports from Business Standard, Hindustan Agrigenetics reported a 25% decline in standalone net profit for the quarter ended June 2026, falling to ₹0.30 crore compared to ₹0.40 crore in the corresponding quarter of the previous year. The company's financial performance showed significant deterioration across key metrics during this quarter.
As reported by Business Standard, the company's sales revenue dropped to nil in the quarter ended June 2026, representing a 100% decline from ₹0.04 crore recorded in the same quarter of the previous year. This complete absence of sales revenue significantly impacted the company's overall financial performance during the quarter.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) remained at 0% in the current quarter, unchanged from the previous year's corresponding quarter. The PBDT (Profit Before Depreciation and Tax) declined by 20% to ₹0.33 crore from ₹0.41 crore in the June 2025 quarter, while PBT (Profit Before Tax) also decreased by 20% to ₹0.32 crore from ₹0.40 crore in the same period last year.
The financial results were reported by Business Standard on August 15, 2026, indicating the company's challenging performance during the June 2026 quarter. The significant decline in profitability across multiple financial metrics reflects the impact of reduced operational activities on Hindustan Agrigenetics' financial performance during this quarter. As of August 14, 2026, the company's share price stood at ₹37.79 with a market capitalization of ₹16.60 crore, showing a -47.06% return over the past year.
